VistaGen Therapeutics
Biopharmaceutical company developing innovative product candidates for patients with diseases and disorders involving the cns.
Launch date
Employees
Market cap
€78.5m
Enterprise valuation
(€18m) (Public information from Sep 2024)
Share price
$3 VTGN
San Francisco California (HQ)
Financials
Estimates*
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.1m | 1.1m | (<1m) | 1.1m | <1m | <1m | 2.5m |
| % growth | - | 2 % | (120 %) | (568 %) | (52 %) | (57 %) | 1032 % |
| EBITDA | (17.8m) | (46.8m) | (59.3m) | (32.5m) | - | - | - |
| % EBITDA margin | (1634 %) | (4222 %) | 26075 % | (3050 %) | - | - | - |
| Profit | (17.9m) | (47.8m) | (59.2m) | (29.4m) | (55.5m) | (77.1m) | (76.3m) |
| % profit margin | (1646 %) | (4307 %) | 26066 % | (2760 %) | (10752 %) | (34909 %) | (3053 %) |
| EV / revenue | 280.2x | 230.9x | -120.3x | 22.1x | 49.9x | -709.7x | 37.8x |
| EV / EBITDA | -17.1x | -5.5x | -0.5x | -0.7x | - | - | - |
| R&D budget | 12.5m | 35.4m | 44.4m | 20.0m | - | - | - |
| R&D % of revenue | 1145 % | 3193 % | (19524 %) | 1882 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
$3.8m | Early VC | ||
$1.0m | Early VC | ||
| N/A | N/A | IPO | |
| N/A | $500k | Debt | |
| N/A | $36.0m | Post IPO Equity | |
| N/A | $1.6m | Early VC | |
| N/A | $1.9m | Early VC | |
| N/A | $10.0m | Post IPO Equity | |
* | $100m | Post IPO Equity | |
| Total Funding | €7.5m | ||
Related Content
Recent News about VistaGen Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by VistaGen Therapeutics
Edit
ACQUISITION by VistaGen Therapeutics Dec 2022